
Oxford BioMedica takes on executive position
pharmafile | August 18, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Oxford BioMedica, blake
Gene and cell therapy firm Oxford BioMedica has confirmed that non-executive director Dr Paul Blake has been appointed to the executive management team as its chief development officer.
Blake will remain a member of the board and will assume responsibility for the clinical development of Oxford BioMedica’s pipeline.
Blake joined the firm in January 2010 and is a senior pharma executive, bringing more than 30 years’ experience within the industry to the UK company.
Most recently, he was senior VP and chief medical officer of biopharma firm Aeterna Zentaris from 2006 to 2014. He was a member of the board at Memory Pharmaceutical until it was purchased by Roche in 2009, and prior to that was a founding member of Protez Pharmaceuticals until it was bought by Novartis in 2008.
Blake’s previous positions also included senior VP and medical director at SmithKline Beecham Pharmaceuticals, now GSK. Prior to that, he worked for ICI Pharmaceuticals, which later became AstraZeneca, and also at GD Searle.
Currently Blake is also a non-executive director of Y-Prime Llc, a clinical trials software and software-as-a-service company.
John Dawson, chief executive of Oxford BioMedica, says: “We are delighted that Paul has accepted the position of chief development officer and chosen to take an executive role within the company at this exciting time for Oxford BioMedica.”
Related Content

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut …

Oxford Biomedica joins forces with UK’s Vaccines Manufacturing and Innovation Centre to scale up production of Oxford Uni’s COVID-19 vaccine
Oxford Biomedica has forged a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) …

Novo Holdings invests £53.5 million into Oxford Biomedica
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for …






